ILB
iShares Government Inflation Etf
🇦🇺 ASX
NULL AUSTRALIA
NULL INCOME
👑 Overview
📈 Performance
📙 Holdings
💰 Distributions
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💰
0.62%
Annual distribution yield
Based on the most recent distribution
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
11
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
ILB.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The fund aims to provide investors with the performance of the Bloomberg AusBond Inflation Government 0+ Yr Index, before fees and expenses. The index is designed to measure the performance of a segment of the Australian bond market comprised of inflation-linked fixed income securities.
📈 Performance
Price History
+25.33%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →📙 Top Holdings
Show more
AUSTRALIA (COMMONWEALTH OF) RegS
7.12%
NEW SOUTH WALES TREASURY CORP
4.47%
QUEENSLAND TREASURY CORP
0.50%
AUST CAPITAL TERRITORY
0.36%
TREASURY CORP VICTORIA
0.01%
Updated as of 13 May 2023
Industry Exposure
📙 Other
100%
Country Exposure
🇦🇺 Australia
100%
💰 Distributions
Payouts
💰 Annual Distribution Yield*
0.62%
💰 Annual Distribution Earnings Per $1,000 invested**
$6.17
💰 Most Recent Distribution Franked Percentage Estimate
0.00%
💰 Average Distribution Franked Percentage Estimate
0.00 %
💰 Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2025
$0.00
0.00%
2024
$0.00
0.00%
2023
$0.21
0.00%
2022
$1.01
0.00%
2021
$0.71
0.00%
2020
$1.32
0.00%
2019
$1.78
0.00%
2018
$1.12
0.00%
2017
$1.01
0.00%
2016
$1.58
0.00%
💵 Costs
💼
0.18%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$125.34
💰 Price To Earnings Ratio
0.00
💰 Price To Book Ratio
0.00
💰 Leveraged
No
💰 Inverse
No
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ILB
11
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in ILB
794 days
ILB investor breakdown
💵 Income of investors
More than 200k
17%
150k - 200k
17%
100k - 150k
17%
50k - 100k
22%
Less than 50k
28%
👶 Age of investors
18 - 25
9%
26 - 34
45%
35 - 90
45%
🙋 Legal gender of investors
Female
45%
Male
55%
Pearlers who invest in ILB also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
VAP.AX was created on 2010-10-11 by Vanguard. The fund's investment portfolio concentrates primarily on real estate equity. Vanguard Australian Property Securities Index Fund seeks to track the return of the S&P/ASX 300 A-REIT Index before taking into account fees, expenses and tax.
📊 Share price
$79.00 AUD
NULL AUSTRALIA
NULL SMART BETA
NULL PROPERTY
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
📊 Share price
$120.79 AUD
NULL AUSTRALIA
NULL BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
Want more shares? Try these...
ILC.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 536.73m in AUM and 21 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of the 20 largest Australian securities listed on the ASX.
📊 Share price
$27.79 AUD
NULL AUSTRALIA
NULL BETA
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm is engaged in drug research and repurposing. The company is focused on developing preventative or therapeutic drugs for viral infections. The firm's lead asset, ISLA-101 is developed by its subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The drug also has the potential to be used to prevent or treat a number of viruses including dengue, Zika and chikungunya, and other diseases rife in tropical climates. The firm is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The firm's subsidiary is Isla Pharmaceuticals Inc.
📊 Share price